David weston: It's a pretty bad week for conglomerates in a great week for break ups. J and j now splitting off a consumer division. And we've seen that among the drug makers who are really focusing on, i guess what some would say, the higher profet pharmaceutical area. All right, let's get to it, and let's bring in our guest.
Dr. Ian Lustbader, Clinical Professor of Medicine at NYU Langone, discusses why the shot-or-test rule makes sense. Bloomberg Businessweek Editor Joel Weber and Bloomberg News U.S. Health Care Reporter Cynthia Koons explain why Covid pills may save lives, but they won’t end the pandemic. Bloomberg News Health Editor John Lauerman talks about Johnson & Johnson's plan to split off its consumer division, following in the footsteps of other big drugmakers that have moved to focus on the more-profitable pharmaceutical market. Kathy Kraninger, VP of Regulatory Affairs at Solidus Labs, shares her thoughts on crypto manipulation and regulation. And We Drive to the Close with Bill Smead, CIO at Smead Capital Management.
Hosts: Carol Massar and Tim Stenovec. Producer: Paul Brennan.
See omnystudio.com/listener for privacy information.